Despite LyP being benign in nature, a majority of cases typically experience relapsing within months to years, while 10%‒40% of patients developing other hematological malignancies or transformation into CD30-positive Anaplastic Large Cell Lymphoma (ALCL), a regular follow-up is recommended even following total remission. Here, TNFRSF8 is linked to hematologic disorder.